Literature DB >> 34149250

Beyond A1C-Standardization of Continuous Glucose Monitoring Reporting: Why It Is Needed and How It Continues to Evolve.

Roy W Beck1, Richard M Bergenstal2.   

Abstract

Continuous glucose monitoring (CGM) systems are becoming part of standard care for type 1 diabetes, and their use is increasing for type 2 diabetes. Consensus has been reached on standardized metrics for reporting CGM data, with time in range of 70-180 mg/dL and time below 54 mg/dL recognized as the key metrics of focus for diabetes management. The ambulatory glucose profile report has emerged as the standard for visualization of CGM data and will continue to evolve to incorporate other elements such as insulin, food, and exercise data to support glycemic management.
© 2021 by the American Diabetes Association.

Entities:  

Year:  2021        PMID： 34149250      PMCID： PMC8178725          DOI： 10.2337/ds20-0090

Source DB:  PubMed          Journal:  Diabetes Spectr        ISSN： 1040-9165


  50 in total

1.  The Relationship of Hemoglobin A1C to Time-in-Range in Patients with Diabetes.

Authors:  Robert A Vigersky; Chantal McMahon
Journal:  Diabetes Technol Ther       Date:  2018-12-21       Impact factor: 6.118

2.  The Fallacy of Average: How Using HbA1c Alone to Assess Glycemic Control Can Be Misleading.

Authors:  Roy W Beck; Crystal G Connor; Deborah M Mullen; David M Wesley; Richard M Bergenstal
Journal:  Diabetes Care       Date:  2017-08       Impact factor: 19.112

3.  Need for Regulatory Change to Incorporate Beyond A1C Glycemic Metrics.

Authors: 
Journal:  Diabetes Care       Date:  2018-06       Impact factor: 19.112

4.  The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c.

Authors:  Roy W Beck; Richard M Bergenstal; Peiyao Cheng; Craig Kollman; Anders L Carlson; Mary L Johnson; David Rodbard
Journal:  J Diabetes Sci Technol       Date:  2019-01-13

5.  Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.

Authors:  Roy W Beck; Richard M Bergenstal; Tonya D Riddlesworth; Craig Kollman; Zhaomian Li; Adam S Brown; Kelly L Close
Journal:  Diabetes Care       Date:  2018-10-23       Impact factor: 19.112

6.  Effect of antecedent hypoglycemia on cognitive function and on glycemic thresholds for counterregulatory hormone secretion in healthy humans.

Authors:  M J Mellman; M R Davis; M Brisman; H Shamoon
Journal:  Diabetes Care       Date:  1994-03       Impact factor: 19.112

Review 7.  The measurement of cognitive function during acute hypoglycaemia: experimental limitations and their effect on the study of hypoglycaemia unawareness.

Authors:  S R Heller; I A Macdonald
Journal:  Diabet Med       Date:  1996-07       Impact factor: 4.359

8.  Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia.

Authors:  S E Dagogo-Jack; S Craft; P E Cryer
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 9.  The Ambulatory Glucose Profile: Opportunities for Enhancement.

Authors:  David Rodbard
Journal:  Diabetes Technol Ther       Date:  2020-12-11       Impact factor: 6.118

10.  Time in Range in Relation to All-Cause and Cardiovascular Mortality in Patients With Type 2 Diabetes: A Prospective Cohort Study.

Authors:  Jingyi Lu; Chunfang Wang; Yun Shen; Lei Chen; Lei Zhang; Jinghao Cai; Wei Lu; Wei Zhu; Gang Hu; Tian Xia; Jian Zhou
Journal:  Diabetes Care       Date:  2020-10-23       Impact factor: 17.152
View more
  1 in total

1.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Richard I G Holt; J Hans DeVries; Amy Hess-Fischl; Irl B Hirsch; M Sue Kirkman; Tomasz Klupa; Barbara Ludwig; Kirsten Nørgaard; Jeremy Pettus; Eric Renard; Jay S Skyler; Frank J Snoek; Ruth S Weinstock; Anne L Peters
Journal:  Diabetologia       Date:  2021-12       Impact factor: 10.122
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.